Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Research and Development | December 16, 2024 | December 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 16, 2024 · Filed December 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,829 |
Reported balance
After 2024-12-16 transaction · row 1
1 source rowRow 1 · 2024-12-16 · Tax withholding · Disposed 304 · Balance 48,829 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,849 |
Reported balance
Holding disclosure · report date 2024-12-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,849 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse as Trustee | 4,605 |
Reported balance
Holding disclosure · report date 2024-12-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,605 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $462.72 | $231,360.00 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,017 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on June 15, 2017 at prices ranging from $462.38 to $462.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 15, 2017 at each separate price. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,295 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · derivative · entry 19 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,295 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 10,822 | $475.56 | $5,146,510.32 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,517 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 906 | $475.56 | $430,857.36 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,339 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 20,295 | $21.25 | $431,268.75 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $483.42 | $96,684.00 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 18 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,950 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 2, 2017 at prices ranging from $483.11 to $483.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 808 | $482.56 | $389,908.48 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 17 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,150 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 808 shares of Company stock on June 2, 2017 at prices ranging from $482.00 to $482.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 695 | $481.64 | $334,739.80 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 16 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,958 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 695 shares of Company stock on June 2, 2017 at prices ranging from $481.25 to $481.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 309 | $480.71 | $148,539.39 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 15 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,653 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 309 shares of Company stock on June 2, 2017 at prices ranging from $480.30 to $480.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $479.00 | $47,900.00 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 14 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,962 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $476.52 | $47,652.00 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 13 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,062 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $475.33 | $47,533.00 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 12 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,162 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $474.82 | $47,482.00 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 11 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,262 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $472.10 | $47,210.00 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 10 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,362 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $470.49 | $47,049.00 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 9 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,462 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $469.83 | $46,983.00 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 8 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,562 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $466.33 | $46,633.00 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,662 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,527 | $0.00 Strike: $268.40 | $0.00 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · derivative · entry 23 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,527 shares Expires 2017-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,017 | $0.00 Strike: $145.70 | $0.00 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · derivative · entry 22 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,017 shares Expires 2017-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,167 | $464.98 | $1,007,611.66 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,762 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,885 | $464.98 | $876,487.30 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,929 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 6,017 | $145.70 | $876,676.90 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,068 | $464.98 | $496,598.64 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,797 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,612 | $464.98 | $1,214,527.76 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,865 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,527 | $268.40 | $1,215,046.80 |
DisclosureSEC source: 0001708138-17-000002 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 21:28 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 58,342 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000094 · edgardoc.xml · derivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,342 Underlying: Common Stock · 58,342 shares Expires 2026-12-16 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 07, 2016 Filed Dec 20, 2016 21:28 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 7,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000094 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,950 Read SEC document |
| February 19, 2016 Filed Dec 20, 2016 21:28 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000094 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,470 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.